Trial Profile
A Phase 2a, Multi-centre, Single-arm Trial of the Combination of AZD2014 and Weekly Paclitaxel in Patients With Relapsed or Refractory Squamous Non-Small Cell Lung Cancer After At Least One Line of Prior Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2018
Price :
$35
*
At a glance
- Drugs Vistusertib (Primary) ; Paclitaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms STORK
- Sponsors AstraZeneca
- 04 Jun 2018 Status has been changed to discontinued.
- 27 Jan 2017 Status changed from active, no longer recruiting to completed.
- 02 Jan 2017 Planned End Date changed from 1 Aug 2016 to 1 Jan 2017.